688108 Sino Medical Sciences Technology Inc.
- 10.81
- -0.17-1.55%
Sino Medical Sciences Technology Inc. News
Express News | Science and Technology Innovation Board Review: Science and Technology Innovation 50 Index closed up 1.14%, and the semiconductor sector rose
China Approves Sino Medical's Intracranial Stent System
China approved Sino Medical Sciences Technology (SHA:688108) subsidiary Sino Medical Science and Technology's product registration for a self-expanding intracranial drug-eluting stent system. The devi
Express News | Sano Medical: Subsidiary's self-inflating intracranial drug-coated stent system application for domestic medical device registration was accepted
Sano Healthcare (688108): Self-expanding intracranial drug-coated stent system successfully accepted and further accelerated the marketing process
The company's star products were successfully accepted for medical device registration by the State Drug Administration, further speeding up marketing. According to the company's “Voluntary Disclosure Notice on Subsidiary Self-Expanding Intracranial Drug-coated Stent Systems to be Accepted for Domestic Medical Device Registration”
Sano Healthcare (688108): Self-expanding intracranial drug-coated stent system enters the FDA registration process
Core view: The company's star products are expected to be approved at an accelerated pace. According to the interactive exchange announced on the Shanghai Stock Exchange Roadshow: The “self-inflating intracranial drug coating stent system” independently developed by the company has received an innovative medical device from the Medical Device Technology Review Center of the State Drug Administration
Express News | Sano Healthcare's self-inflating intracranial drug-coated stents are currently in the process of registration
Sano Healthcare (688108.SH): Currently, the business mainly covers key areas of interventional treatment such as cardiovascular, cerebrovascular, and structural heart diseases
Gelonghui, May 10 | Sano Healthcare (688108.SH) said on the investor interactive platform that the company is an international company rooted in China, targeting the global market, and focusing on R&D, production and sales of high-end interventional medical devices. Currently, the company's business mainly covers key areas of interventional treatment such as cardiovascular, cerebrovascular, and structural heart diseases.
Sano Healthcare (688108): Coronary collection and intracranial stent volume are increasing rapidly, and profits are expected for the whole year
Event: The company released its 2023 annual report and 2024 quarterly report: in 2023, the company achieved operating income of 343 million yuan (+77.9%), net profit to mother of 39.63 million yuan (+75.6%), deducted from non-return
Sano Healthcare (688108): 23-year performance is in line with expectations, and the 25-year release of dense mesh stents and self-expanding drug stents can be expected
Incident: The company released its 2023 annual report, achieved revenue of 340 million yuan (+78%), realized net profit of 39.63 million yuan (year-on-year loss of 120 million yuan), and realized deduction of 49.71 million yuan. 2024 quarter
Sano Healthcare (688108): Coronary collection, rapid renewal, and sufficient room for intracranial self-inflating stents to grow
Key investment events: In 2023, the company achieved operating income of 340 million yuan (+77.99%, same ratio, same below), achieved net profit of 39.63 million yuan (reversal of loss of 123 million yuan), and realized net profit deducted from non-return to mother-
Sino Medical Sciences Technology Inc. (SHSE:688108) Surges 13%; Retail Investors Who Own 41% Shares Profited Along With Insiders
Key Insights Significant control over Sino Medical Sciences Technology by retail investors implies that the general public has more power to influence management and governance-related decisions The
Sano Healthcare (688108.SH) reported 2023 annual results with a net loss of 39.63 million yuan
Sano Healthcare (688108.SH) released its 2023 annual report. The company achieved operating income of 3 during the reporting period...
Sano Healthcare (688108): 23 years of performance have drastically reduced losses, and the company's main products continue to advance
Core view: The company's 23-year performance was in line with expectations, and net profit to mother was drastically reduced. According to the company's annual report for 23 years, the company achieved revenue of 343 million yuan (YOY +77.99%), of which the revenue from coronary and neurological intervention businesses was different
Sano Healthcare (688108.SH): Product obtained registration certificate in Belarus
On April 18, GLONGHUI (688108.SH) announced that in December 2023, the company submitted registration data for the company's HT SupremeTM drug-eluting stents, NCROCKSTARTM non-compliant balloon dilatation catheters, and SC HONKYTONKTM coronary balloon dilation catheters to the Ministry of Health of Belarus (“MOH” for short). The company recently received a notice from MOH, the company HT SupremeTM drug-eluting stents, NC ROCKSTART non-compliant balloon expansion catheter, SC HONK
Express News | Sano Healthcare: The subsidiary Sano Shenchang self-inflating intracranial drug-coated stent system passed a special review process for innovative medical devices
Sano Healthcare (688108.SH): The company's products obtained a registration certificate in Korea
On March 15, GLONGHUI (688108.SH) announced that in November 2022 and May 2023, the company submitted registration data for the company's HTSUPremetM drug-eluting stent, NCROCKSTART non-compliant balloon dilatation catheter, and SCHONKYTONKTM coronary balloon dilation catheter to the Korean Ministry of Food and Drug Safety (hereinafter referred to as “MFDS”), respectively. The company recently received an MFDS notification that the company HTSUPremetM drug-eluting stents and NCROCKSTARTM non-compliant balloon dilatation
There's Reason For Concern Over Sino Medical Sciences Technology Inc.'s (SHSE:688108) Massive 41% Price Jump
Sino Medical Sciences Technology Inc. (SHSE:688108) shareholders are no doubt pleased to see that the share price has bounced 41% in the last month, although it is still struggling to make up recently
Express News | Sano Healthcare: The company's products obtained a registration certificate in Pakistan
A-share changes丨Sano Healthcare rose more than 6% and recently recovered the previous decline. The product obtained a registration certificate in Hong Kong
GLONGHUI March 5 | Sano Healthcare (688108.SH) rose more than 6% to reach 11.3 yuan, completely recovering the previous decline and hitting a one-and-a-half-month high, with a total market value of 4.64 billion yuan. Yesterday's after-market announcement. The company recently received a notice from MDD. The company's HT Supreme drug-eluting stent system was approved by the Medical Device Division (MDD) of the Hong Kong Department of Health. Furthermore, the recently announced 23-year results were in line with expectations, and net profit to mother was drastically reduced.
Sano Healthcare (688108.SH): HT Supreme drug-eluting stent system obtained registration certificate in Hong Kong, China
Sano Healthcare (688108.SH) announced that in September 2022, the company told the Medical Device Division of the Hong Kong Department of Health, China...
Analysis
Price Target
No Data
